000 04400nam a22006375i 4500
999 _c200457537
_d75749
003 DE-He213
005 20231109085817.0
007 cr nn 008mamaa
008 220809s2022 sz | s |||| 0|eng d
020 _a9783030977443
024 7 _a10.1007/978-3-030-97744-3
_2doi
040 _aTR-AnTOB
_beng
_cTR-AnTOB
_erda
060 0 0 _aWG 120
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
072 7 _aMJCL
_2thema
096 _aWG120EBK
245 1 0 _aCardio-Oncology
_h[electronic resource] :
_bManagement of Toxicities in the Era of Immunotherapy /
_cedited by Antonio Russo, Nicola Maurea, Dimitrios Farmakis, Antonio Giordano.
250 _a1st ed. 2022.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Humana,
_c2022.
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCurrent Clinical Pathology,
_x2197-7828
505 0 _a1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.
520 _aThe development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.
650 0 _aOncology.
650 0 _aCardiology.
650 0 _aPathology.
650 0 _aInternal medicine.
650 1 4 _aOncology.
650 2 4 _aCardiology.
650 2 4 _aPathology.
650 2 4 _aInternal Medicine.
653 0 _aCardiovascular Diseases -- etiology
653 0 _aCardiotoxicity -- complications
653 0 _aNeoplasms -- drug therapy
653 0 _aAntineoplastic Agents -- toxicity
653 0 _aCardiotoxicity -- therapy
653 0 _aCancer Survivors
700 1 _aRusso, Antonio.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aMaurea, Nicola.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aFarmakis, Dimitrios.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aGiordano, Antonio.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
830 0 _aCurrent Clinical Pathology,
_x2197-7828
856 4 0 _uhttps://doi.org/10.1007/978-3-030-97744-3
_3Springer eBooks
_zOnline access link to the resource
942 _2NLM
_cEBK
041 _aeng